| Literature DB >> 33660425 |
Alexander L Schneider1, Robert P Schleimer1,2, Bruce K Tan1,2.
Abstract
Chronic rhinosinusitis with nasal polyps (CRSwNP) represents a challenging disease entity with significant rates of recurrence following appropriate medical and surgical therapy. Recent approval of targeted biologics in CRSwNP compels deeper understanding of underlying disease pathophysiology. Both of the approved biologics for CRSwNP modulate the type 2 inflammatory pathway, and the majority of drugs in the clinical trials pathway are similarly targeted. However, there remain multiple other pathogenic mechanisms relevant to CRSwNP for which targeted therapeutics already exist in other inflammatory diseases that have not been studied directly. In this article we summarize pathogenic mechanisms of interest in CRSwNP and discuss the results of ongoing clinical studies of targeted therapeutics in CRSwNP and other related human inflammatory diseases.Entities:
Keywords: biologic therapies; chronic rhinosinusitis with nasal polyps; type 2 inflammation
Mesh:
Substances:
Year: 2021 PMID: 33660425 PMCID: PMC8316260 DOI: 10.1002/alr.22787
Source DB: PubMed Journal: Int Forum Allergy Rhinol ISSN: 2042-6976 Impact factor: 5.426